Skip to main content
Karyopharm Therapeutics Inc. (KPTIQ)
OTCMKTS · Delayed Price · Currency is USD
0.0254
-0.0001 (-0.39%)
At close: Nov 13, 2026

Karyopharm Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
146.62146.07145.24146.03157.07209.82
Revenue Growth
6.81%0.57%-0.55%-7.03%-25.14%94.12%
Gross Profit
145.25140.12139.23141.09151.86206.42
Operating Income
-82.35-90.71-119.44-129.54-142.2-98.27
Net Income
-224.74-196.04-76.42-143.1-165.29-124.09
Earnings Per Share
-11.58-17.93-14.00-18.79-30.30-24.75
EPS Growth
------

Cash & Debt
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
65.1163.74108.71191.44277.97228.62
Total Debt
328.53305.95268.02309.5311.79313.58
Net Cash (Debt)
-263.43-242.2-159.31-118.05-33.83-84.96
Net Cash Growth
------
Net Cash Per Share
-13.57-22.15-18.84-15.50-6.20-16.94

Cash Flow & CapEx
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-65.35-75.37-127.49-92.72-149.55-107.12
Capital Expenditures
---0.14--0.12-0.21
Free Cash Flow
-65.35-75.37-127.63-92.72-149.67-107.33
Free Cash Flow Growth
------

Margins
Chart
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
99.06%95.93%95.86%96.62%96.68%98.38%
Operating Margin
-56.16%-62.10%-82.24%-88.71%-90.53%-46.84%
Pretax Margin
-153.30%-134.18%-52.58%-97.77%-105.00%-59.01%
Profit Margin
-153.28%-134.21%-52.62%-97.99%-105.23%-59.14%
FCF Margin
-44.57%-51.60%-87.88%-63.50%-95.29%-51.15%

Valuation
Chart
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
0.000.920.590.682.452.32